±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 172  |  »Ø¸´: 0
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

mkyye

¾èÖú¹ó±ö (ÖªÃû×÷¼Ò)

×öÈËÒª´óÆø£¬ÐÄÐØÒª¿í¹ã

[½»Á÷] Ò©ÎïÁÙ´²ÊÔÑé³£ÓÃÃû´ÊÊÍÒå

Ò©ÎïÁÙ´²ÊÔÑé³£ÓÃÃû´ÊÊÍÒå


Ãû´ÊÊÍÒå

1£®ÁÙ´²ÊÔÑ飨Clinical Trial£©£ºÖ¸ÈκÎÔÚÈËÌ壨²¡ÈË»ò½¡¿µÖ¾Ô¸ÕßÉíÉÏ£©½øÐÐÒ©Æ·µÄϵͳÐÔÑо¿£¬ÒÔ֤ʵ»ò½ÒʾÑо¿Ò©Æ·µÄ×÷Óᢲ»Á¼·´Ó¦¼°£¯»òÊÔÑéÓÃÒ©Æ·µÄÎüÊÕ¡¢·Ö²¼¡¢´úлºÍÅÅй£¬Ä¿µÄÊÇÈ·¶¨Ñо¿Ò©Æ·µÄÁÆÐ§Ó밲ȫÐÔ¡£

2£®ÊÔÑé·½°¸£¨Protoco1£©£ºÐðÊöÊÔÑéµÄ±³¾°¡¢ÀíÂÛ»ù´¡ºÍÄ¿µÄ£¬ÊÔÑéÉè¼Æ¡¢·½·¨ºÍ×éÖ¯£¬°üÀ¨Í³¼ÆÑ§¿¼ÂÇ¡¢ÊÔÑéÖ´ÐкÍÍê³ÉµÄÌõ¼þ¡£·½°¸±ØÐëÓɲμÓÊÔÑéµÄÖ÷ÒªÑо¿Õß¡¢Ñо¿»ú¹¹ºÍÉê°ìÕßǩղ¢×¢Ã÷ÈÕÆÚ¡£

3.Ñо¿ÕßÊֲᣨInvestigator's Brochure£©£ºÊÇÓйØÊÔÑéÓÃÒ©Æ·ÔÚ½øÐÐÈËÌåÑо¿Ê±ÒÑÓеÄÁÙ´²Óë·ÇÁÙ´²×ÊÁÏ¡£

4£®ÖªÇéͬÒ⣨Informed Consent£©£ºÖ¸ÏòÊÜÊÔÕ߸æÖªÒ»ÏîÊÔÑéµÄ¸÷¸ö·½ÃæÇé¿öºó£¬ÊÜÊÔÕß×ÔԸȷÈÏÆäͬÒâ²Î¼Ó¸ÃÏîÁÙ´²ÊÔÑéµÄ¹ý³Ì£¬ÐëÒÔÇ©ÃûºÍ×¢Ã÷ÈÕÆÚµÄÖªÇéͬÒâÊé×÷ΪÎļþÖ¤Ã÷¡£

5£®ÖªÇéͬÒâÊ飨Informed Consent form£©£ºÊÇÿλÊÜÊÔÕß±íʾ×ÔÔ¸²Î¼ÓijһÊÔÑéµÄÎļþÖ¤Ã÷¡£Ñо¿Õß±ØÐëÏòÊÜÊÔÕß˵Ã÷ÊÔÑéÐÔÖÊ¡¢ÊÔÑéÄ¿µÄ¡¢¿ÉÄܵÄÊÜÒæºÍΣÏÕ¡¢¿É¹©Ñ¡ÓÃµÄÆäËûÖÎÁÆ·½·¨ÒÔ¼°·ûºÏ¡¶ºÕ¶ûÐÁ»ùÐûÑÔ¡·¹æ¶¨µÄÊÜÊÔÕßµÄȨÀûºÍÒåÎñµÈ£¬Ê¹ÊÜÊÔÕß³ä·ÖÁ˽âºó±í´ïÆäͬÒâ¡£

6£®Â×ÀíίԱ»á£¨Ethics Committee£©£ºÓÉҽѧרҵÈËÔ±¡¢·¨ÂÉר¼Ò¼°·ÇÒ½ÎñÈËÔ±×é³ÉµÄ¶ÀÁ¢×éÖ¯£¬ÆäÖ°ÔðΪºË²éÁÙ´²ÊÔÑé·½°¸¼°¸½¼þÊÇ·ñºÏºõµÀµÂ£¬²¢ÎªÖ®Ìṩ¹«ÖÚ±£Ö¤£¬È·±£ÊÜÊÔÕߵݲȫ¡¢½¡¿µºÍÈ¨ÒæÊܵ½±£»¤¡£¸ÃίԱ»áµÄ×é³ÉºÍÒ»Çл²»Ó¦ÊÜÁÙ´²ÊÔÑé×éÖ¯ºÍʵʩÕߵĸÉÈÅ»òÓ°Ïì¡£

7£®Ñо¿Õߣ¨Investigator)£ºÊµÊ©ÁÙ´²ÊÔÑé²¢¶ÔÁÙ´²ÊÔÑéµÄÖÊÁ¿ºÍÊÜÊÔÕߵݲȫºÍÈ¨ÒæµÄ¸ºÔðÕß¡£Ñо¿Õß±ØÐë¾­¹ý×ʸñÉó²é£¬¾ßÓÐÁÙ´²ÊÔÑéµÄ×¨ÒµÌØ³¤¡¢×ʸñºÍÄÜÁ¦¡£ÔÚ¶àÖÐÐÄÁÙ´²ÊÔÑéÖУ¬ÓÉÒ»ÃûÖ÷ÒªÑо¿Õß¶ÔÁÙ´²ÊÔÑéʵʩ×ܸºÔ𣬲¢×÷Ϊ¸÷ÊÔÑéÖÐÐļäµÄЭµ÷ÈË¡£

8£®Ð­µ÷Ñо¿Õߣ¨Coordinating Investigator)£ºÔÚ¶àÖÐÐÄÁÙ´²ÊÔÑéÖиºÔðЭµ÷¸÷²Î¼ÓÖÐÐĵÄÑо¿ÕߵŤ×÷µÄÒ»ÃûÑо¿Õß¡£

9.É걨Ö÷°ìÕߣ¨Sponsor£©£º¼ò³ÆÉê°ìÕߣ¬·¢ÆðÒ»ÏîÁÙ´²ÊÔÑ飬²¢¶Ô¸ÃÊÔÑéµÄÆô¶¯¡¢¹ÜÀí¡¢²ÆÎñºÍ¼àÊÓ¸ºÔðµÄ¹«Ë¾¡¢»ú¹¹»ò×éÖ¯¡£

10£®¼à²éÔ±£¨Monitor£©£ºÓÉÉê°ìÕßÈÎÃü²¢¶ÔÉê°ìÕ߸ºÔðµÄ¾ß±¸Ïà¹ØÖªÊ¶µÄÈËÔ±£¬ÆäÈÎÎñÊǼà²éºÍ±¨¸æÊÔÑéµÄ½øÐÐÇé¿öºÍºËʵÊý¾Ý¡£

l1£®»ü²é£¨Audit£©£ºÖ¸Óɲ»Éæ¼°ÊÔÑéµÄÈËÔ±Ëù½øÐеÄÒ»ÖÖϵͳÐÔ¼ì²é£¬ÒÔÅж¨ÊÔÑéµÄʵʩ¡¢Êý¾ÝµÄ¼Ç¼ºÍ·ÖÎöÊÇ·ñÓëÊÔÑé·½°¸¡¢Ò©Æ·ÁÙ´²ÊÔÑé¹ÜÀí¹æ·¶¼°·¨¹æÒªÇóÏà·û¡£

12£®ÊӲ죨Inspection£©£ºÒ©Æ·¼à¶½¹ÜÀí²¿ÃŶÔÓйØÒ»ÏîÁÙ´²ÊÔÑéµÄÎļþ¡¢ÉèÊ©¡¢¼Ç¼ºÍÆäËû·½Ãæ½øÐйٷ½ÉóÔÄ£¬ÊÓ²ì¿ÉÒÔÔÚÊÔÑ鵥λ¡¢Éê°ìÕßËùÔڵػòºÏͬÑо¿×éÖ¯ËùÔڵؽøÐС£

13£®²¡Àý±¨¸æ±í£¨Case Report form, CRF£©£ºÖ¸°´ÊÔÑé·½°¸Ëù¹æ¶¨Éè¼ÆµÄÒ»ÖÖÎļþ£¬ÓÃÒԼǼÿһÃûÊÜÊÔÕßÔÚÊÔÑé¹ý³ÌÖеÄÊý¾Ý¡£

14£®×ܽᱨ¸æ£¨Final Report£©£ºÊÔÑéÍê³ÉºóµÄÒ»·ÝÏ꾡×ܽᣬ°üÀ¨ÊÔÑé·½·¨Óë²ÄÁÏ¡¢½á¹ûµÄÃèÊöÓëÆÀ¹À¡¢Í³¼Æ·ÖÎöÒÔ¼°×îÖÕËù»ñ¼ø¶¨ÐԵġ¢ºÏºõµÀµÂµÄͳ¼ÆÑ§ºÍÁÙ´²ÆÀ¼Û±¨¸æ¡£

15.Ò©Æ·£¨Pharmaceutical Product£©£ºÖ¸ÓÃÓÚÔ¤·À¡¢ÖÎÁÆ¡¢Õï¶ÏÈ˵ļ²²¡£¬ÓÐÄ¿µÄµØµ÷½ÚÈ˵ÄÉúÀí»úÄܲ¢¹æ¶¨ÓÐÊÊÓ¦Ö¤¡¢Ó÷¨ºÍÓÃÁ¿µÄÎïÖÊ¡£

16£®ÊÔÑéÓÃÒ©Æ·£¨Investigational Product£©£ºÁÙ´²ÊÔÑéÖÐÓÃ×÷ÊÔÑé»ò²Î±ÈµÄÈκÎÒ©Æ·»ò°²Î¿¼Á¡£

17£®Ò©Æ·²»Á¼·´Ó¦£¨Adverse Drug Reaction£©£ºÔÚ°´¹æ¶¨¼ÁÁ¿Õý³£Ó¦ÓÃÒ©Æ·µÄ¹ý³ÌÖвúÉúµÄÓꦶø·ÇËùÆÚÍûµÄ¡¢ÓëÒ©Æ·Ó¦ÓÃÓÐÒò¹û¹ØÏµµÄ·´Ó¦¡£ÔÚÒ»ÖÖÐÂÒ©»òÒ©Æ·µÄÐÂÓÃ;µÄÁÙ´²ÊÔÑéÖУ¬ÆäÖÎÁƼÁÁ¿ÉÐδȷ¶¨Ê±£¬ËùÓÐÓꦶø·ÇËùÆÚÍûµÄ¡¢ÓëÒ©Æ·Ó¦ÓÃÓÐÒò¹û¹ØÏµµÄ·´Ó¦£¬Ò²Ó¦ÊÓΪҩƷ²»Á¼·´Ó¦¡£

18£®²»Á¼Ê¼þ£¨Adverse Event£©£º²¡ÈË»òÁÙ´²ÊÔÑéÊÜÊÔÕß½ÓÊÜÒ»ÖÖÒ©Æ·ºó³öÏֵIJ»Á¼Ò½Ñ§Ê¼þ£¬µ«²¢²»Ò»¶¨ÓëÖÎÁÆÓÐÒò¹û¹ØÏµ¡£

19£®ÑÏÖØ²»Á¼Ê¼þ£¨Serious Adverse Event£©£ºÁÙ´²ÊÔÑé¹ý³ÌÖз¢ÉúÐèסԺÖÎÁÆ¡¢ÑÓ³¤×¡ÔºÊ±¼ä¡¢É˲С¢Ó°Ï칤×÷ÄÜÁ¦¡¢Î£¼°ÉúÃü»òËÀÍö¡¢µ¼ÖÂÏÈÌì»ûÐεÈʼþ¡£

20£®±ê×¼²Ù×÷³ÌÐò£¨Standard Operating Procedure,SOP£©:ΪÓÐЧµØÊµÊ©ºÍÍê³ÉijһÁÙ´²ÊÔÑéÖÐÿÏ×÷ËùÄⶨµÄ±ê×¼¶øÏêϸµÄÊéÃæ¹æ³Ì¡£

21£®Éè䣨Blinding£¯Masking£©ÁÙ´²ÊÔÑéÖÐʹһ·½»ò¶à·½²»ÖªµÀÊÜÊÔÕßÖÎÁÆ·ÖÅäµÄ³ÌÐò¡£µ¥Ã¤Ö¸ÊÜÊÔÕß²»Öª£¬Ë«Ã¤Ö¸ÊÜÊÔÕß¡¢Ñо¿Õß¡¢¼à²éÔ±»òÊý¾Ý·ÖÎöÕß¾ù²»ÖªÖÎÁÆ·ÖÅä¡£

22£®ÖÊÁ¿¿ØÖÆ(Quality Control)£ºÓÃÒÔ±£Ö¤ÓëÁÙ´²ÊÔÑéÏà¹Ø»î¶¯µÄÖÊÁ¿´ïµ½ÒªÇóµÄ²Ù×÷ÐÔ¼¼ÊõºÍ³ÌÐò¡£

23£®ºÏͬÑо¿×éÖ¯£¨Contract Research Organization, CRO£©£ºÒ»ÖÖѧÊõÐÔ»òÉÌÒµÐԵĿÆÑ§»ú¹¹¡£Éê°ìÕß¿ÉίÍÐÆäÖ´ÐÐÁÙ´²ÊÔÑéÖеÄijЩ¹¤×÷ºÍÈÎÎñ£¬´ËÖÖίÍбØÐë×÷³öÊéÃæ¹æ¶¨¡£
»Ø¸´´ËÂ¥
Ð黳Èô¹È
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ mkyye µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 325·Ö»¯Ñ§µ÷¼Á +5 15771691647 2026-04-02 5/250 2026-04-03 09:58 by ChemPharm
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +12 Ò»ÑùYWY 2026-04-02 12/600 2026-04-03 09:46 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 321Çóµ÷¼Á +6 ÈÏÕæÇóÉÏѧ 2026-04-02 6/300 2026-04-03 09:33 by ÒÅÍüÏûʧµÄž™
[¿¼ÑÐ] Çóµ÷¼Á£¡ÉúÎïÓëҽҩר˶ +4 Äæ×ªÂ½ÏÈÉú 2026-04-01 5/250 2026-04-03 08:33 by Jaylen.
[¿¼ÑÐ] 306·Ö²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +3 Àè°ÉÀ²À²ÄãºÜÓÐà 2026-04-03 3/150 2026-04-03 08:14 by laura9751
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +8 ÀÁÑòÑòÇáÖÃÓñÍÎ 2026-04-02 8/400 2026-04-02 22:03 by liu823948201
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +7 Ò»ÑùYWY 2026-04-02 7/350 2026-04-02 21:49 by dongzh2009
[¿¼ÑÐ] ²ÄÁÏר˶322·Ö +10 ¹þ¹þ¹þºðºðºð¹þ 2026-04-02 10/500 2026-04-02 21:46 by dongzh2009
[¿¼ÑÐ] ÇóÉúÎïѧµ÷¼Á +10 15172915737 2026-04-01 10/500 2026-04-02 18:53 by ŶŶàŹþ
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉϺ£º£Ñó´óѧ083200ʳƷѧ˶£¬Çóµ÷¼Á£¬½ÓÊÜÆäËûרҵ +6 whatÕÅ 2026-04-01 7/350 2026-04-02 16:48 by zzsw+
[¿¼ÑÐ] 285Çóµ÷¼Á +14 AZMK 2026-04-02 14/700 2026-04-02 15:54 by ÉϾÅÌìÀ¿Ô£¨ºÃÔ
[¿¼²©] ²ÄÁϹ¤³Ìרҵ˶ʿÉ격 +3 ÷ëÕýÓî 2026-03-30 3/150 2026-04-02 15:04 by greychen00
[¿¼ÑÐ] 377Çóµ÷¼Á +3 RASKIN 2026-04-02 3/150 2026-04-02 09:45 by zzchen2000
[¿¼ÑÐ] 348»·¾³¹¤³Ìµ÷¼Á +3 ÎâÑå׿24k 2026-04-01 3/150 2026-04-02 09:14 by nanaliuyun
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸ÄϾ©Ê¦·¶´óѧ¼ÆËã»úר˶£¬³õÊÔ373£¬Áù¼¶Í¨¹ý£¬ +3 ¼ÆËã»ú×·ÃÎÈË 2026-04-01 3/150 2026-04-02 07:57 by fxue1114
[¿¼ÑÐ] 333Çóµ÷¼Á +4 °¢¿ÆÒÝ 2026-03-31 4/200 2026-04-01 09:11 by jp9609
[¿¼ÑÐ] Çóµ÷¼Á +9 akdhjs 2026-03-31 10/500 2026-03-31 17:14 by zhyzzh
[¿¼ÑÐ] ±¾¿Æ211ÉúÎïҽѧ¹¤³Ì085409Çóµ÷¼Á339·Ö +7 Àï×Óľyy 2026-03-29 7/350 2026-03-31 14:35 by fmesaito
[Óлú½»Á÷] ¼×»ùÑǻǻÇËáÄÆºÍ¼×»ù»ÇËáõ¥·´Ó¦»úÀí 10+3 kaobao456 2026-03-29 4/200 2026-03-30 23:16 by nBuï®
[¿¼ÑÐ] 328Çóµ÷¼Á +8 àŵεĻù±¾¶¼ 2026-03-27 8/400 2026-03-30 17:20 by Wang200018
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û